I s meperidine past its prime? Does it still belong on your formulary?
The Agency for Health Care Policy and Research Clinical Practice (AHCPR) and American Pain Society guidelines recommend that meperidine not be used if continued opioid use is anticipated for acute or chronic pain. Instead, meperidine should be used only briefly for the treatment of acute pain in patients who have documented allergic reactions or intolerance to other opioid analgesics or for the management of rigors (shivering) induced by other medications. Meperidine should not be used continuously (ie, for more than 48 hours) or for any pain conditions that might require more than several days of therapy. 1, 2, 3, 4 When meperidine is prescribed, it is generally underprescribed in terms of dose and dosing interval. The duration of meperidine's analgesic activity is only 2 to 4 hours, despite a half-life of 3 to 5 hours, and this effect appears to decrease with chronic dosing. Meperidine's oral bioavailability is 50% to 60%, so the oral dose should be higher than the IV dose. However, oral administration of meperidine is not encouraged. The maximum dose of meperidine is 600 mg per 24 hours and therapy should be limited to less than 48 hours. 4, 5, 6, 7 Accumulation of normeperidine, a toxic metabolite of meperidine that is predominately excreted by the kidney, can occur at any time in patients with renal dysfunction or in patients receiving high-dose therapy. Levels of normeperidine can also be increased when patients receive CYP 2D6 inducers (eg, rifampin, carbamazepine, bar-biturates, phenytoin). The risk of normeperidine toxicity also increases when meperidine is given to patients receiving ritonavir. The half-life of normeperidine is 15 to 30 hours in patients with normal renal function. As the level of normeperidine increases, so does the risk of seizures, dysphoria, and irritable mood, even in relative healthy younger patients. 2, 3, 4, 5, 6, 7, 8 Meperidine is contraindicated in patients with renal dysfunction or patients receiving monoamine oxidase inhibitors (MAOIs) (eg, isocarboxazid, phenelzine, tranylcypromine, selegiline). 2, 3, 5, 7, 9 The administration of meperidine in elderly patients is discouraged because of their decreased renal function.
Meperidine should be used with caution in patients with gastrointestinal obstruction, ileus, ulcerative colitis, pre-existing constipation, pulmonary disease, respiratory depression, history of substance abuse, head trauma, increased intracranial pressure, glaucoma, hepatic disease, pregnancy, seizure disorders, cardiac arrhythmias, urinary retention, oliguria, and the elderly. 5, 7 Opiate agonists may increase the tone of biliary tract and cause spasms. Meperidine has traditionally been used over morphine because it causes lesspronounced changes in frequency and amplitude in the sphincter of Oddi than does morphine. 5, 10 However, there are no reports that meperidine is safer in patients with acute pancreatitis. 10 Additive depression of the respiratory and central nervous system and increased risk of severe constipation are risks with most opiate analgesics when used with other agents that cause all or some of these same adverse effects. Meperidine has several unique drug interactions that are not associated with some of the opiate analgesics. The risk of serotonin syndrome is increased when meperidine is used in combination with serotoninreceptor agonists, serotonin-reuptake inhibitors, St. John's Wort, lithium, and sibutramine. Serious cardiovascular and neurologic adverse reactions (eg, hyperexcitability, convulsions, tachycardia, hyperpyrexia, hypertension) can occur when meperidine is used with MAOIs. The same risk may occur when the drug is used with agents that have some MAOI activity (eg, furazolidone, isoniazid, linezolid, procarbazine). 5, 7, 9, 11 In some facilities, meperidine is still used as a first-line agent in the treatment of pain when it should be restricted to second-or third-line use and possibly removed from the formulary. The frequent use of this agent by some prescribers is not good patient care and does not help us decrease avoidable drug-induced injuries.
The first step in the process of ensuring appropriate meperidine use is to prevent administration of the drug to any patient for more than 2 days. Patients should be periodically monitored for signs and symptoms of normeperidine toxicity (eg, tremor, twitching, jerking, seizures).
The next step is to conduct a utilization review of meperidine in your institution. A utilization review data collection form for meperidine was published by The Formulary Monograph Service, a Facts and Comparisons publication, in March 2001. This form could be used as a template for this project. Once the data is collected and tabulated, it should be shared with the appropriate medical committees within your institution, along with any preprinted analgesic orders for patient-controlled analgesia or postoperative analgesia that include meperidine as an option. These committees should review meperidine utilization patterns and determine if guidelines or restrictions need to be implemented to decrease use of the agent.
Another method would be to read the article by Gordon et al. ("A quality improvement approach to reduce use of meperidine") 12 and use it as a template to decrease the use of this potentially dangerous analgesic that is past its prime.
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